甘精胰岛素联合诺和龙对2型糖尿病患者胰岛功能及TNF-α,IL-6的影响
|
摘要
目的研究甘精胰岛素联合诺和龙对于高血糖状态的初发2型糖尿病患者胰岛功能、TNF-α及IL-6的作用.方法选取初发2型糖尿病高血糖状态患者120例,随机平均分为观察组和对照组,每组60例.两组患者均给予糖尿病饮食控制、运动训练和健康知识讲座等基本治疗.对照组在此基础上予以诺和灵30R治疗;观察组在此基础上予以甘精胰岛素联合诺和龙治疗.治疗3个月后复查患者TNF-α、IL-6、胰岛素水平和低血糖事件发生率.结果观察组患者空腹胰岛素水平显著低于对照组(P<0.05),而餐后2 h胰岛素水平显著高于对照组(P<0.05),差异具有统计学意义.观察组患者TNF-α,IL-6水平均显著低于对照组(P<0.05),差异具有统计学意义.低血糖事件发生率观察组显著低于对照组(P<0.05),差异具有统计学意义.结论甘精胰岛素联合诺和龙控制血糖效果好,能有效改善2型糖尿病高血糖状态患者体内胰岛功能,同时降低TNF-α,IL-6水平.
Objective To investigate the effects of insulin glargine combined with Novonorm on islet function,TNF-α and IL-6 in patients with newly diagnosed type 2 diabetes mellitus in hyperglycemia. Method 120 patients with newly diagnosed type 2 diabetes hyperglycemia were randomly divided into two groups,the observation group and the control group,with 60 cases in each group.The patients of two groups were given basic treatments such as diabetes diet,exercise training and disease knowledge education. On the basis of this,the control group was treated with Novo-Ling 30 R; the observation group was treated with insulin glargine combined with Novonorm.After 3 months of treatment,TNF-α,IL-6,insulin levels and the incidence of hypoglycemia events were reviewed.Results The fasting insulin level in the observation group was significantly lower than that in the control group( P < 0.05),and the insulin level after 2 hours the meal was significantly higher than that in the control group( P < 0. 05). The difference was statistically significant. The levels of TNF-α and IL-6 in the observation group were significantly lower than those in the control group( P < 0. 05),and the difference was statistically significant.The incidence of hypoglycemia in the observation group was significantly lower than that in the control group( P < 0. 05),and the difference was statistically significant. Conclusion Insulin glargine combined with Novonorm has good glycemic control effect,can effectively improve islet function in patients with type 2 diabetes hyperglycemia,is not prone to hypoglycemia,and simultaneously reduces TNF-α and IL-6 levels,and has a certain effect on preventing insulin resistance and atherosclerosis.
Objective To investigate the effects of insulin glargine combined with Novonorm on islet function,TNF-α and IL-6 in patients with newly diagnosed type 2 diabetes mellitus in hyperglycemia. Method 120 patients with newly diagnosed type 2 diabetes hyperglycemia were randomly divided into two groups,the observation group and the control group,with 60 cases in each group.The patients of two groups were given basic treatments such as diabetes diet,exercise training and disease knowledge education. On the basis of this,the control group was treated with Novo-Ling 30 R; the observation group was treated with insulin glargine combined with Novonorm.After 3 months of treatment,TNF-α,IL-6,insulin levels and the incidence of hypoglycemia events were reviewed.Results The fasting insulin level in the observation group was significantly lower than that in the control group( P < 0.05),and the insulin level after 2 hours the meal was significantly higher than that in the control group( P < 0. 05). The difference was statistically significant. The levels of TNF-α and IL-6 in the observation group were significantly lower than those in the control group( P < 0. 05),and the difference was statistically significant.The incidence of hypoglycemia in the observation group was significantly lower than that in the control group( P < 0. 05),and the difference was statistically significant. Conclusion Insulin glargine combined with Novonorm has good glycemic control effect,can effectively improve islet function in patients with type 2 diabetes hyperglycemia,is not prone to hypoglycemia,and simultaneously reduces TNF-α and IL-6 levels,and has a certain effect on preventing insulin resistance and atherosclerosis.
引文
[1]郑红英.2型糖尿病患者生活质量及抑郁状况的调查与分析[J].临床护理杂志,2010,9(5):10-12.
[2]张黎明,高凌.炎症细胞因子在2型糖尿病发病机制中的研究进展[J].重庆医学,2016,45(8):1113-1116.
[3]王玲霞.甘精胰岛素联合诺合龙在2型糖尿病初始胰岛素治疗中的作用[J].中国社区医师(医学专业半月刊),2009,11(15):33-34.
[4]罗玲,袁丽,严艳.简明饮食处方对初诊2型糖尿病干预的效果分析[J].护士进修杂志,2010,25(23):2165-2167.
[5]熊加红,李显文.诺和龙及甘精胰岛素联合治疗老年2型糖尿病的疗效观察[J].医学信息(上旬刊),2011,24(7):4136-4137.
[6]田爽.甘精胰岛联合诺和龙治疗2型糖尿病的疗效观察[J].吉林医学,2013,34(6):1066.
[7]颜薇,陈秋.2型糖尿病/胰岛素抵抗炎症机制的浅析[J].时珍国医国药,2012,23(9):2299-2300.
[8]牟晓华,王家琳.肥胖型2型糖尿病胰岛素抵抗机制及治疗研究[J].中医药临床杂志,2015,27(8):1063-1066.
[9]房万菊,魏刚.糖尿病伴肥胖患者胰岛素抵抗程度评估及与血清学指标的关系[J].海南医学院学报,2015,21(10):1352-1354,1357.
[10]陈燕铭,王一娜,钟毅敏,等.2型糖尿病视网膜病变患者血清炎症因子和脂联素水平的变化[J].中国病理生理杂志,2011,27(6):1154-1158.
[11]沈寒蕾,赖战峰,谭晓丹,等.2型糖尿病患者血浆内脂素与炎症因子的相关性研究[J].中国现代医学杂志,2012,22(7):44-47.
[12]陈燕铭,熊肇军,尹琼丽,等.2型糖尿病患者血清炎症因子和脂联素水平与动脉粥样硬化的关系[J].中国动脉硬化杂志,2011,19(10):842-846.
[13]杨帆,杨立,许旌,等.老年2型糖尿病患者的炎症因子水平与认知功能障碍的关系[J].卒中与神经疾病,2014,21(3):169-173.
[14]张晓坤,孙曙光.IL-6、C反应蛋白与2型糖尿病并发症的关系研究进展[J].中国医学创新,2014,11(35):153-156.
[15]荣佐民.甘精胰岛素联合应用诺和龙治疗2型糖尿病的临床观察[J].中国医疗前沿,2012,7(6):19.
[16]柳沙利,郭莹婧.预混胰岛素治疗血糖控制不佳的2型糖尿病患者改为甘精胰岛素联合瑞格列奈100例疗效观察[J].吉林医学,2011,32(10):1943-1944.
[17]胡艳芳,王秋平.口服药联合甘精胰岛素治疗2型糖尿病观察[J].当代医学,2012,18(11):98.
[18]王艳梅.甘精胰岛素联合诺和龙强化治疗初发2型糖尿病临床疗效分析[J].临床医药文献电子杂志,2017,4(55):10840.
[19]简强,李佳,李鹏飞.瑞格列奈治疗2型糖尿病并动脉硬化患者的疗效[J].心血管康复医学杂志,2016,25(2):192-194.
[20]曾世敏.甘精胰岛素联合诺和龙治疗初诊2型糖尿病疗效观察[J].实用预防医学,2009,16(1):189-190.
[2]张黎明,高凌.炎症细胞因子在2型糖尿病发病机制中的研究进展[J].重庆医学,2016,45(8):1113-1116.
[3]王玲霞.甘精胰岛素联合诺合龙在2型糖尿病初始胰岛素治疗中的作用[J].中国社区医师(医学专业半月刊),2009,11(15):33-34.
[4]罗玲,袁丽,严艳.简明饮食处方对初诊2型糖尿病干预的效果分析[J].护士进修杂志,2010,25(23):2165-2167.
[5]熊加红,李显文.诺和龙及甘精胰岛素联合治疗老年2型糖尿病的疗效观察[J].医学信息(上旬刊),2011,24(7):4136-4137.
[6]田爽.甘精胰岛联合诺和龙治疗2型糖尿病的疗效观察[J].吉林医学,2013,34(6):1066.
[7]颜薇,陈秋.2型糖尿病/胰岛素抵抗炎症机制的浅析[J].时珍国医国药,2012,23(9):2299-2300.
[8]牟晓华,王家琳.肥胖型2型糖尿病胰岛素抵抗机制及治疗研究[J].中医药临床杂志,2015,27(8):1063-1066.
[9]房万菊,魏刚.糖尿病伴肥胖患者胰岛素抵抗程度评估及与血清学指标的关系[J].海南医学院学报,2015,21(10):1352-1354,1357.
[10]陈燕铭,王一娜,钟毅敏,等.2型糖尿病视网膜病变患者血清炎症因子和脂联素水平的变化[J].中国病理生理杂志,2011,27(6):1154-1158.
[11]沈寒蕾,赖战峰,谭晓丹,等.2型糖尿病患者血浆内脂素与炎症因子的相关性研究[J].中国现代医学杂志,2012,22(7):44-47.
[12]陈燕铭,熊肇军,尹琼丽,等.2型糖尿病患者血清炎症因子和脂联素水平与动脉粥样硬化的关系[J].中国动脉硬化杂志,2011,19(10):842-846.
[13]杨帆,杨立,许旌,等.老年2型糖尿病患者的炎症因子水平与认知功能障碍的关系[J].卒中与神经疾病,2014,21(3):169-173.
[14]张晓坤,孙曙光.IL-6、C反应蛋白与2型糖尿病并发症的关系研究进展[J].中国医学创新,2014,11(35):153-156.
[15]荣佐民.甘精胰岛素联合应用诺和龙治疗2型糖尿病的临床观察[J].中国医疗前沿,2012,7(6):19.
[16]柳沙利,郭莹婧.预混胰岛素治疗血糖控制不佳的2型糖尿病患者改为甘精胰岛素联合瑞格列奈100例疗效观察[J].吉林医学,2011,32(10):1943-1944.
[17]胡艳芳,王秋平.口服药联合甘精胰岛素治疗2型糖尿病观察[J].当代医学,2012,18(11):98.
[18]王艳梅.甘精胰岛素联合诺和龙强化治疗初发2型糖尿病临床疗效分析[J].临床医药文献电子杂志,2017,4(55):10840.
[19]简强,李佳,李鹏飞.瑞格列奈治疗2型糖尿病并动脉硬化患者的疗效[J].心血管康复医学杂志,2016,25(2):192-194.
[20]曾世敏.甘精胰岛素联合诺和龙治疗初诊2型糖尿病疗效观察[J].实用预防医学,2009,16(1):189-190.